▶ GLP-1 / GIP DUAL AGONIST · SUBTOPIC · SAFETY PROFILE
GLP-1 / GIP DUAL AGONIST Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GLP-1 / GIP DUAL AGONIST.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GLP-1 / GIP DUAL AGONIST. Severity, frequency, and attribution depend on the source publication.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis (rare, boxed-warning caution)
- Gallbladder disease (rare)
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GLP-1 / GIP DUAL AGONIST.
- Oral contraceptives (delayed gastric emptying may alter absorption)
- Sulfonylureas / insulin (hypoglycemia risk)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GLP-1 / GIP DUAL AGONIST in the published record:
- Personal/family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
FDA REGULATORY STATUS
Approved as an FDA-approved class member (T2D, May 2022) and the FDA-approved class member (chronic weight management, Nov 2023). Compounded versions restricted since FDA shortage declaration lifted Oct 2024.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ What's the difference between separate FDA-approved class members?
Same molecule, different label. the FDA-approved class member is FDA-approved for type 2 diabetes (May 2022). the FDA-approved class member is the same compound rebranded for chronic weight management (Nov 2023). Different concentrations and titration schedules per label.
▶ How is the GLP-1 / GIP dual agonist dosed?
Per FDA label, the GLP-1 / GIP dual agonist is titrated weekly: 2.5 mg starting → 5 mg → up to 15 mg over months. This wiki reproduces the label dose schedule for reference only; any human use should be under qualified clinical supervision.
▶ Is compounded the GLP-1 / GIP dual agonist still legal?
FDA declared the the GLP-1 / GIP dual agonist shortage resolved October 2024, restricting compounding under section 503A. Research-grade the GLP-1 / GIP dual agonist sold as a chemical reference compound is distinct from compounded human-use formulations and is supplied here for in-vitro research only.
▶ Does the GLP-1 / GIP dual agonist cause thyroid cancer?
Class-based rodent C-cell tumor signal led to a boxed warning. Translation to human relevance is debated; current clinical data have not established a causal link, but personal or family history of medullary thyroid carcinoma is a contraindication.
▶ Is the GLP-1 / GIP dual agonist banned in sports?
Not currently on the WADA Prohibited List as of 2026. Status reviewable annually.
▶ What's the difference between the GLP-1 / GIP dual agonist research-grade and the FDA-approved class member/the FDA-approved class member?
The active molecule is the same. Branded human-prescription products are formulated, labeled, and quality-controlled to FDA pharmaceutical standards under separate clinical pathways. Research-grade material is a chemical reference compound for laboratory use only.
▶ the GLP-1 / GIP dual agonist for OSA · what does the research show?
The SURMOUNT-OSA program reported significant reductions in the apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity treated with the GLP-1 / GIP dual agonist. FDA approved the GLP-1 / GIP dual agonist (the FDA-approved class member) for moderate-to-severe OSA in adults with obesity in December 2024. Mechanism is thought to be a combination of direct weight-loss effects and indirect effects on upper-airway tissue.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. the GLP-1 / GIP dual agonist Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. link
- Frías JP, Davies MJ, Rosenstock J, et al.. the GLP-1 / GIP dual agonist versus the long-acting GLP-1 agonist Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021. link
- Horn DB, Aronne LJ, Wharton S, et al.. the GLP-1 / GIP dual agonist for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026. PMID 42119587. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19